Vasalgel

Vasalgel wordmark

Update!

The Parsemus Foundation and its social venture subsidiary Revolution Contraceptives, LLC have partnered with NEXT Life Sciences to continue development of the Vasalgel male contraceptive.

Vasalgel has a new home

After a decade of research on Vasalgel, the Parsemus Foundation determined that the reversible, long-lasting male contraceptive was ready to advance to the next level. The search began for an organization with the resources needed to lead the project to the marketplace, including clinical trials and regulatory review. The Parsemus Foundation selected NEXT Life Sciences, Inc. as that partner. NEXT Life Sciences’ mission is to develop and distribute medical technology that empowers people to choose when and whether to have a child. 

For more information, see our blog post and the NEXT press release.

NEXT logo on blue ground

How to stay engaged with Vasalgel

Stay Connected

Visit the NEXT Life Sciences website

  • Visit the NEXT LifeSciences website to get more information on Vasalgel.

Reproductive Health News

NEXT logo on blue ground

NEXT steps for Vasalgel

The Parsemus Foundation and Revolution Contraceptives LLC are pleased to announce that NEXT Life Sciences, Inc. has been selected to continue development of the Vasalgel

Read More
NEXT logo on blue ground

NEXT steps for Vasalgel

The Parsemus Foundation and Revolution Contraceptives LLC are pleased to announce that NEXT Life Sciences, Inc. has been selected to continue development of the Vasalgel

Read More
We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today